Using Integrated Care and Wearable Technology to Evaluate Outcomes of the Shields & Stripes Program for Veterans and First Responders (S&S Wellness)

March 6, 2026 updated by: Kelli Cabrera, Baylor University

Evaluating Integrated Care and Wearable Technology Outcomes in the Shields & Stripes Program for Veterans and First Responders: A Retrospective Mixed-Methods Study

This study aims to evaluate outcomes from the Shields & Stripes (S&S) program - a 12-week, multidisciplinary wellness intervention designed for veterans and first responders. The S&S program integrates occupational therapy (OT), mental health (MH), physical therapy (PT), and registered dietitian (RD) services to promote recovery, resilience, and performance in individuals who have experienced cumulative stress, trauma exposure, or occupational burnout.

This research will use a retrospective mixed-methods observational design to analyze data collected from previous S&S participants who consent to research use of their de-identified information. No intervention or treatment changes will occur as part of this study.

Quantitative data will include biometric information (e.g., sleep, activity, and heart rate variability via Oura Ring), standardized self-report measures (GAD-7, PHQ-9, PCL-5, RAND-36, PSQI, ISI), satisfaction surveys, and laboratory nutrition panels. Qualitative data will include semi-structured interviews with consenting participants and S&S providers following program completion.

The purpose of the study is to identify patterns of improvement in physical, psychological, and occupational functioning and to explore how integrated, team-based care supports holistic recovery. Findings may inform the development of future evidence-based wellness programs for military and first-responder populations.

Participation involves minimal risk, and all data will be de-identified before analysis.

Study Overview

Detailed Description

Study Overview This retrospective mixed-methods observational study evaluates the effectiveness of the Shields & Stripes (S&S) program, a 12-week integrated wellness model that combines occupational therapy (OT), mental health (MH) services, physical therapy (PT), and registered dietitian (RD) support. The program serves veterans and first responders who experience cumulative physical, cognitive, and emotional stress related to their service.

The study will retrospectively analyze quantitative and qualitative data from S&S cohorts between 2024-2026 to assess changes in health, functioning, and quality of life.

Objectives

Evaluate changes in physical, psychological, and occupational functioning following participation in S&S.

Explore relationships between biometric indicators (e.g., heart-rate variability, sleep, activity) and self-reported well-being.

Examine trends in nutrition and metabolic markers across cohorts.

Analyze participant and provider perspectives through qualitative interviews to better understand mechanisms of change and perceived program value.

Design and Methods

Design: Convergent mixed-methods retrospective observational study.

Quantitative Data: Includes biometric data (sleep, HRV, activity), self-report scales (GAD-7, PHQ-9, PCL-5, RAND-36, PSQI, ISI), and laboratory measures (cholesterol, glucose regulation, vitamin D, testosterone, thyroid, inflammatory markers, etc.).

Qualitative Data: Semi-structured interviews with consenting participants and providers conducted post-program (via teleconference).

Participants: Veterans and first responders aged 18-70 who have completed the S&S program and program providers who have worked within the S&S program.

Recruitment: No direct external recruitment will occur for this study. All participants will be drawn from existing Shields & Stripes program cohorts and affiliated program providers, which utilize processes separate from this research.

Data Handling: All data will be de-identified prior to analysis; stored securely on encrypted, access-restricted cloud servers.

Primary Outcomes

Change in self-reported anxiety (GAD-7)

Change in depressive symptoms (PHQ-9)

Change in PTSD symptoms (PCL-5)

Change in sleep (PSQI and ISI)

Change in quality of life (RAND-36)

Change in sleep quality and recovery metrics (Oura Ring data)

Secondary Outcomes

Changes in nutritional and metabolic lab results (e.g., cholesterol, glucose, vitamin D, thyroid function).

Qualitative themes related to perceived program benefit, barriers, and provider perspectives.

Duration and Setting Data will be collected retrospectively from cohorts between 2024-2026. The study will take place remotely with data stored and analyzed by the research team.

Risk and Safeguards The study is minimal risk. No interventions or procedures are performed beyond standard program participation. Risks are limited to potential discomfort during interviews and minimal risk of confidentiality breach, mitigated through HIPAA-compliant data handling.

Expected Impact Results will inform how multidisciplinary programs combining OT, MH, PT, and RD services improve functional, psychological, and physiological outcomes among high-stress occupational populations. The study aims to contribute to the evidence base for integrated, holistic wellness approaches for veterans and first responders.

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Texas
      • Waco, Texas, United States, 76798
        • Baylor University - Department of Occupational Therapy
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of U.S. military veterans and first responders who have participated in the Shields & Stripes 12-week multidisciplinary wellness program. The program integrates occupational therapy, mental health, physical therapy, and nutrition services. All data analyzed will be collected post-program completion, making the study primarily retrospective.

Description

Inclusion Criteria:

  • Adults aged 18-70 years
  • Current or former members of the U.S. Armed Forces or first responder professions (e.g., law enforcement, firefighting, EMS)
  • Participants who completed the Shields & Stripes holistic wellness program
  • Providers who worked within the Shields and Stripes program.

Exclusion Criteria:

-None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Shields & Stripes Program Participants

Participants include veterans and first responders who have completed the 12-week Shields & Stripes holistic wellness program. The program integrates occupational therapy, mental health, physical therapy, and registered dietitian services to address physical, psychological, and occupational functioning.

Data analyzed for this study include de-identified biometric, psychological, and laboratory outcomes collected as part of standard program procedures. Past and present program providers will also serve as participants to gain a better understanding of the program and its impact. No additional interventions are introduced for research purposes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Psychological Functioning Generalized Anxiety Disorder 7-item (GAD-7) scale
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

To assess changes in anxiety symptoms before and after participation in the 12-week Shields & Stripes program using validated self-report measures.

Score range: 0 to 21

Higher scores indicate: Worse anxiety symptoms

Baseline (Week 0) to Post-Program (Week 12)
Change in Psychological Functioning utilizing Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

To assess changes in depression symptoms before and after participation in the 12-week Shields & Stripes program using validated self-report measures.

Score range: 0 to 27

Higher scores indicate: Worse depressive symptoms

Baseline (Week 0) to Post-Program (Week 12)
Change in Psychological Functioning utilizing the Posttraumatic Stress Disorder Checklist (PCL-5)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

To assess changes in post-traumatic stress symptoms before and after participation in the 12-week Shields & Stripes program using validated self-report measures.

Score range: 0 to 80

Higher scores indicate: Worse PTSD symptoms

Baseline (Week 0) to Post-Program (Week 12)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Heart Rate Variability (HRV)
Time Frame: Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Change in heart rate variability as measured by the Oura Ring wearable device. HRV will be reported as the nightly average root mean square of successive differences (RMSSD).

Time Frame:

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Unit of Measure:

Milliseconds (ms)

Directionality:

Higher values indicate better autonomic nervous system balance and recovery.

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)
Change in Sleep Quality - Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), a validated 19-item self-report questionnaire assessing sleep quality and disturbances over the past month.

Time Frame:

Baseline (Week 0) to Post-Program (Week 12)

Unit of Measure:

Total PSQI global score (range: 0 to 21)

Directionality:

Higher scores indicate worse sleep quality.

Baseline (Week 0) to Post-Program (Week 12)
Change in Health-Related Quality of Life - RAND 36-Item Health Survey (RAND-36)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in health-related quality of life as measured by the RAND 36-Item Health Survey (RAND-36), a validated self-report questionnaire assessing eight domains including physical functioning, role limitations (physical and emotional), energy/fatigue, emotional well-being, social functioning, pain, and general health perceptions.

Time Frame:

Baseline (Week 0) to Post-Program (Week 12)

Unit of Measure:

RAND-36 subscale scores transformed to a 0-100 scale.

Directionality:

Higher scores indicate better health-related quality of life and functioning.

Baseline (Week 0) to Post-Program (Week 12)
Qualitative Themes from Semi-Structured Interviews
Time Frame: Post-Program (within 4 weeks of completion)

Participant and provider feedback will be collected using a semi-structured interview guide developed for this study. Thematic analysis will identify recurring themes related to participant satisfaction, perceived effectiveness, and experiences with integrated occupational therapy, mental health, physical therapy, and nutrition services.

Time Frame: Post-Program (within 4 weeks of completion) Unit of Measure: Not applicable (qualitative thematic analysis)

Post-Program (within 4 weeks of completion)
Change in Physical Function and Performance (PSFS)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in self-reported physical function measured by the Patient-Specific Functional Scale (PSFS), reflecting improvements in self-identified functional goals and mobility.

Time Frame: Baseline (Week 0) to Post-Program (Week 12) Unit of Measure: Mean PSFS total score (0-10 scale) Directionality: Higher scores indicate better functional performance

Baseline (Week 0) to Post-Program (Week 12)
Change in Sleep Duration
Time Frame: Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Change in total nightly sleep duration as measured by the Oura Ring wearable device.

Time Frame:

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Unit of Measure:

Hours (or minutes - choose one and stay consistent)

Directionality:

Higher values indicate longer sleep duration

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)
Change in Sleep Efficiency
Time Frame: Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Change in sleep efficiency as measured by the Oura Ring wearable device. Sleep efficiency is calculated as the percentage of time in bed spent asleep.

Time Frame:

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Unit of Measure:

Percentage (%)

Directionality:

Higher values indicate better sleep quality.

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)
Change in Resting Heart Rate
Time Frame: Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Change in resting heart rate as measured by the Oura Ring wearable device.

Time Frame:

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Unit of Measure:

Beats per minute (bpm)

Directionality:

Lower values generally indicate better cardiovascular fitness and recovery.

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)
Change in Physical Activity Level
Time Frame: Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)

Change in average daily activity level as measured by the Oura Ring wearable device.

Unit of Measure:

Oura Activity Score (0-100 scale)

Directionality:

Higher values indicate greater physical activity.

Pre-Program (T-4 weeks), Program Start (Week 0), and Post-Program (Week 12)
Change in Insomnia Severity - Insomnia Severity Index (ISI)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in insomnia symptom severity as measured by the Insomnia Severity Index (ISI), a validated 7-item self-report questionnaire assessing perceived insomnia severity.

Time Frame:

Baseline (Week 0) to Post-Program (Week 12)

Unit of Measure:

Total ISI score (range: 0 to 28)

Directionality:

Higher scores indicate more severe insomnia symptoms.

Baseline (Week 0) to Post-Program (Week 12)
Change in Total Cholesterol
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in total cholesterol measured via standard laboratory testing.

Unit of Measure:

mg/dL

Directionality:

Lower values indicate improved lipid profile.

Baseline (Week 0) to Post-Program (Week 12)
Change in HDL Cholesterol
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in high-density lipoprotein (HDL) cholesterol measured via standard laboratory testing.

Unit of Measure:

mg/dL

Directionality:

Higher values indicate improved lipid profile.

Baseline (Week 0) to Post-Program (Week 12)
Change in LDL Cholesterol
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Change in low-density lipoprotein (LDL) cholesterol measured via standard laboratory testing.

Unit of Measure:

mg/dL

Directionality:

Lower values indicate improved lipid profile.

Baseline (Week 0) to Post-Program (Week 12)
Change in Triglycerides
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Description:

Change in triglyceride levels measured via standard laboratory testing.

Unit of Measure:

mg/dL

Directionality:

Lower values indicate improved lipid profile.

Baseline (Week 0) to Post-Program (Week 12)
Change in Fasting Glucose
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Description:

Change in fasting blood glucose measured via standard laboratory testing.

Unit of Measure:

mg/dL

Directionality:

Lower values indicate improved glycemic control.

Baseline (Week 0) to Post-Program (Week 12)
Change in Hemoglobin A1c (HbA1c)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Description:

Change in hemoglobin A1c (HbA1c), a measure of average blood glucose over approximately three months, measured via standard laboratory testing.

Unit of Measure:

Percent (%)

Directionality:

Lower values indicate improved glycemic control.

Baseline (Week 0) to Post-Program (Week 12)
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Description:

Change in high-sensitivity C-reactive protein (hs-CRP), a biomarker of systemic inflammation, measured via standard laboratory testing.

Unit of Measure:

mg/L

Directionality:

Lower values indicate reduced systemic inflammation.

Baseline (Week 0) to Post-Program (Week 12)
Change in Vitamin D (25-hydroxyvitamin D)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Description:

Change in serum 25-hydroxyvitamin D levels measured via standard laboratory testing.

Unit of Measure:

ng/mL

Directionality:

Higher values indicate improvement toward normal vitamin D status.

Baseline (Week 0) to Post-Program (Week 12)
Change in Thyroid Stimulating Hormone (TSH)
Time Frame: Baseline (Week 0) to Post-Program (Week 12)

Description:

Change in thyroid stimulating hormone (TSH) levels measured via standard laboratory testing.

Unit of Measure:

mIU/L

Directionality:

Movement toward the normal reference range indicates improved thyroid function.

Baseline (Week 0) to Post-Program (Week 12)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

April 30, 2027

Study Registration Dates

First Submitted

November 12, 2025

First Submitted That Met QC Criteria

February 27, 2026

First Posted (Actual)

March 5, 2026

Study Record Updates

Last Update Posted (Actual)

March 10, 2026

Last Update Submitted That Met QC Criteria

March 6, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This study involves retrospective analysis of de-identified data collected from participants in the Shields & Stripes program. Individual participant data (IPD) will not be shared with other researchers outside the study team. Only aggregated, de-identified results will be reported in publications and presentations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on PTSD

Subscribe